Daiichi Sankyo replaces head of its Ranbaxy unit

New Delhi Mon May 25, 2009 1:26pm IST

Malvinder Singh speaks during a news conference in New Delhi in this June 11, 2008 file photo. REUTERS/Danish Ismail/Files

Malvinder Singh speaks during a news conference in New Delhi in this June 11, 2008 file photo.

Credit: Reuters/Danish Ismail/Files

Related Topics

New Delhi (Reuters) - Japanese drugmaker Daiichi Sankyo said Malvinder Singh, chairman and chief executive of its Indian unit Ranbaxy Laboratories, had resigned and named replacements for him on Sunday.

On May 12, Japan's third-biggest drugmaker forecast its full-year profit would be well below expectations, blaming losses at Ranbaxy and saying it planned to get actively involved in resolving its unit's problems.

Non-executive director Tsutomu Une was named chairman while Atul Sobti, Ranbaxy's chief operating officer, was promoted to chief executive and managing director.

New chairman Une told reporters the move was aimed at "accelerating growth" of Ranbaxy. "The separation was amicable."

Ranbaxy has been hit by a U.S. ban on some products for alleged falsification of data, and by foreign exchange hedges being hit by a weaker rupee.

Last year, Daiichi Sankyo bought a 63.9 percent stake, including the founders' entire stake, in Ranbaxy, aiming to take advantage of rising demand for generic drugs.

But the stake lost more than two thirds of its value by the end of financial year primarily hit by the weak rupee and the U.S. FDA ban. Last month, Ranbaxy forecast a loss of $150 million in 2009, on a 9 percent fall in sales to $1.4 billion.

Ranbaxy and Daiichi Sankyo have said they are working with the U.S. FDA, and new CEO Sobti said the company was on track to meet with the FDA soon. The firm also said there was no plan to delist Ranbaxy.

Malvinder Singh's exit came within a year of selling the company his grandfather began building half a century ago.

"It was a difficult decision to separate from Ranbaxy," said Singh, who took over as chief executive in 2006.

Earlier, the Economic Times daily said Singh's tenure at the helm was scheduled to end in 2013 and he was entitled to a severance package of 450 million rupees ($9.6 million) if he left the company before. Une, when asked about the severance package, said the company would proceed according to the employment agreement. He did not elaborate.

Ranbaxy shares are down 12.5 percent so far in 2009 compared with a 44 percent rise in the benchmark index

($1 = 47.1 rupees)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Markets

REUTERS SHOWCASE

Segway in India

Segway in India

Segway’s India business pegs hope on tech-savvy Modi  Full Article 

Power Outage

Power Outage

Mumbai hit by power cuts  Full Article 

Commodities

Commodities

Gold imports, premiums to jump on festive demand - top refiner  Full Article 

Economic Worries

Economic Worries

Pakistan's promises to IMF in doubt as protests sap economy   Full Article 

Islamic Finance

Islamic Finance

Basel III deposit challenge looms over Islamic banks   Full Article 

Antitrust Probes

Antitrust Probes

U.S. business lobby says concerned China antitrust probes unfair.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage